Reata Pharma (RETA) Tops Q3 EPS by 89c; Reports Cash and Cash Equivalents of $713.2M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
November 8, 2021 6:40 AM ESTAdvisory Committee Meeting for Bardoxolone for Patients With CKD Caused by Alport Syndrome Scheduled for December 8, 2021
Submitted MAA to the EMA for Bardoxolone for Patients With CKD Caused by Alport Syndrome in October 2021
Planned NDA Submission for Omaveloxolone in the First Quarter of 2022 Following Completion of Pre-NDA Meeting With FDA
Conference Call With Management on November 8, 2021 at 8:30 a.m. ET
PLANO, Texas--(BUSINESS... More
